Key Highlights: Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a promising new therapy for treating ALS. The results showed that Ellorarxine increases MAP2 expression at low concentrations, induces neurite outgrowth, ameliorates neuroinflammation and modifies GluA2 expression. Nevrargenics is now proceeding to human trials with Ellorarxine, after receiving the green light from the MHRA.
A peer reviewed study published in the International Journal of Molecular Sciences by academics led by Wolfson Fellow Paul Chazot has shown that a new treatment for the most common type of motor neurone disease could improve the neuronal health of sufferers and allow their nervous systems to improve regeneration.
Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a promising new therapy for treating ALS. The disease is the most common motor neurone disease (MND) and is characterised by progressive muscle atrophy, the wasting of muscle mass. It affects over 5000 people in the UK at any one time.
To read the full article please click here.
/prod01/prodbucket01/media/durham-university/research-/research-institutes/wolfson-research-institute/60056.jpg)